Mystic receives research grant for VersiDoser delivery platform
Mystic Pharmaceuticals will spend the money on progressing its blister-based delivery technology
Mystic Pharmaceuticals Inc a specialty pharmaceutical company focused on the development of advanced precision ophthalmic and intranasal delivery technologies for drugs and biologics, has been awarded a non-taxable grant of approximately US$245,000 related to its VersiDoser Delivery Platform under the Qualifying Therapeutic Discovery Project (QTDP) programme included in the Patient Protection and Affordable Health Care Act of 2010.
To be eligible for the QTDP programme, projects must show reasonable potential to result in new therapies to treat areas of unmet medical need; prevent, detect, or treat chronic or acute disease and conditions; reduce long-term health care costs in the US; or significantly advance the goal of curing cancer within a 30-year period.
Mystic Pharmaceuticals, based in Austin, Texas, provides precision unit dose delivery systems for pharmaceuticals and biologics for ophthalmic and system intranasal applications. Mystic partners with pharmaceutical and biotech manufacturers to combine its novel delivery systems with a pipeline of pharmaceuticals and biologics to meet the expanding global market demand for healthcare products that are safer, simpler and cost effective.
In particular, its VersiDoser delivery platform uses a proprietary manufacturing process to produce unit dose, liquid filled blisters. VersiDose Blisters are produced using USP monograph tested laminates that provide superior barrier properties against water vapour, oxygen and light transmission.
The blisters are formed, filled and sealed via a proprietary aseptic manufacturing process. Each blister is precision filled with the drug compound, sealed and loaded into a Mystic delivery system. VersiDoser blister incorporates a proprietary VelocityJet micro pump, which controls precision dosing, delivery and spray plume geometry. The VersiDoser blister can be configured to accommodate a variety of drug compounds or biologic agents, with delivered dose capabilities ranging from 15 to 500 microliters.
VersiDoser Blisters can also be terminally sterilised if required. There are single and multi-dose delivery systems for intranasal and ophthalmic applications available.
